The Hunt for the Next 10 Bagger

[MG123]

HTDS

SHENZEN, CHINA--(Marketwire - 03/03/11) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (www.htdsmedical.com) announced today that its China-based Shenzhen Mellow Hope subsidiary is planning a seminar for Indian medical experts.

The Indian experts are expected in China for the seminar and will visit Chinese medical experts in Beijing, Shanghai and Shenzhen. They will discuss plans to market 'Cognistar' (Cerebroprotein Hydrolysate for Injection) in India. Mellow Hope believes that this product will receive wide acceptance in the Indian market and has huge growth potential.

Mellow Hope finished the clinical trials of Cerebroprotein Hydrolysate for Injection in India. This biological product is a unique nutriment for the brain that helps the central nervous system in multiple ways, including: regulating and improving nerve cell metabolism; promoting synapse generation; inducing nerve cell differentiation; and protecting nerve cells against damages by ischemia and neurotoxins.

Mellow Hope looks forward to the visit from the Indian medical experts and plans to update investors as these developments progress.